OptimizeRx Statistics
Total Valuation
OptimizeRx has a market cap or net worth of $82.71 million. The enterprise value is $101.01 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
OptimizeRx has 18.42 million shares outstanding. The number of shares has increased by 6.86% in one year.
| Current Share Class | 18.42M |
| Shares Outstanding | 18.42M |
| Shares Change (YoY) | +6.86% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 12.46% |
| Owned by Institutions (%) | 65.22% |
| Float | 15.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 17.75 |
| PS Ratio | 0.91 |
| Forward PS | 0.72 |
| PB Ratio | 0.71 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.23, with a Debt / Equity ratio of 0.31.
| Current Ratio | 3.23 |
| Quick Ratio | 2.93 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.25 |
Financial Efficiency
Return on equity (ROE) is -20.97% and return on invested capital (ROIC) is -3.55%.
| Return on Equity (ROE) | -20.97% |
| Return on Assets (ROA) | -3.27% |
| Return on Capital (ROIC) | -3.55% |
| Revenue Per Employee | $648,379 |
| Profits Per Employee | -$177,749 |
| Employee Count | 136 |
| Asset Turnover | 0.61 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -9.16M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.19% in the last 52 weeks. The beta is 1.32, so OptimizeRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.32 |
| 52-Week Price Change | -55.19% |
| 50-Day Moving Average | 6.36 |
| 200-Day Moving Average | 9.95 |
| Relative Strength Index (RSI) | 38.28 |
| Average Volume (20 Days) | 351,970 |
Short Selling Information
The latest short interest is 956,303, so 5.19% of the outstanding shares have been sold short.
| Short Interest | 956,303 |
| Short Previous Month | 912,485 |
| Short % of Shares Out | 5.19% |
| Short % of Float | 6.35% |
| Short Ratio (days to cover) | 6.62 |
Income Statement
In the last 12 months, OptimizeRx had revenue of $88.18 million and -$24.17 million in losses. Loss per share was -$1.34.
| Revenue | 88.18M |
| Gross Profit | 55.20M |
| Operating Income | -7.57M |
| Pretax Income | -25.32M |
| Net Income | -24.17M |
| EBITDA | -3.54M |
| EBIT | -7.57M |
| Loss Per Share | -$1.34 |
Full Income StatementBalance Sheet
The company has $16.13 million in cash and $35.72 million in debt, giving a net cash position of -$19.59 million or -$1.06 per share.
| Cash & Cash Equivalents | 16.13M |
| Total Debt | 35.72M |
| Net Cash | -19.59M |
| Net Cash Per Share | -$1.06 |
| Equity (Book Value) | 114.47M |
| Book Value Per Share | 6.25 |
| Working Capital | 32.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.57 million and capital expenditures -$100,073, giving a free cash flow of -$1.67 million.
| Operating Cash Flow | -1.57M |
| Capital Expenditures | -100,073 |
| Free Cash Flow | -1.67M |
| FCF Per Share | -$0.09 |
Full Cash Flow StatementMargins
Gross margin is 62.59%, with operating and profit margins of -8.59% and -27.41%.
| Gross Margin | 62.59% |
| Operating Margin | -8.59% |
| Pretax Margin | -37.80% |
| Profit Margin | -27.41% |
| EBITDA Margin | -4.01% |
| EBIT Margin | -8.59% |
| FCF Margin | -7.45% |
Dividends & Yields
OptimizeRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.86% |
| Shareholder Yield | -6.86% |
| Earnings Yield | -29.96% |
| FCF Yield | -2.07% |
Analyst Forecast
The average price target for OptimizeRx is $8.80, which is 95.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.80 |
| Price Target Difference | 95.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 14, 2018. It was a reverse split with a ratio of 0.33333:1.
| Last Split Date | May 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.33333:1 |
Scores
OptimizeRx has an Altman Z-Score of 2.25 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.25 |
| Piotroski F-Score | 3 |